title: Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3.
abstract: A phase I/II study of intraperitoneal (ip) radioimmunotherapy was conducted in ovarian or breast cancer patients with symptomatic chemotherapy-resistant ascites using a novel anti-mucin monoclonal antibody (mAb) 2G3 labeled with 131I. Tracer doses of 2 mCi [131I]2G3 were given by ip injection to 11 patients, followed by increasing therapeutic doses up to 150 mCi (cumulative) in 9 patients. There was no serious toxicity. Temporary palliation of ascites was observed in 3 of 4 patients who received doses greater than 50 mCi. Total body elimination half-life of the radiolabeled antibody assessed by gamma scintigraphy ranged from 95 to 250 hr, longer than data previously reported in patients without ascites treated with ip administered radiolabeled antibodies. However, uptake of radiolabel by tumor nodules was small and variable (2 x 10(-4) - 2 x 10(-2) % ID/g), and preferential uptake by tumor compared to normal peritoneum was observed in only 2 of 5 patients in whom biopsies were obtained. These results suggest that the observed palliation of ascites is due to prolonged retention of radiolabeled antibody in the peritoneal cavity even in the absence of specific targeting.
authors.affiliation: Toronto Bayview Regional Cancer Centre, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Buckman
authors.forename: C
authors.initials: C
authors.lastname: De Angelis
authors.forename: P
authors.initials: P
authors.lastname: Shaw
authors.forename: A
authors.initials: A
authors.lastname: Covens
authors.forename: R
authors.initials: R
authors.lastname: Osborne
authors.forename: I
authors.initials: I
authors.lastname: Kerr
authors.forename: R
authors.initials: R
authors.lastname: Reed
authors.forename: H
authors.initials: H
authors.lastname: Michaels
authors.forename: M
authors.initials: M
authors.lastname: Woo
authors.forename: R
authors.initials: R
authors.lastname: Reilly
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001201:Ascites / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007457:Iodine Radioisotopes; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes